NasdaqCM - Nasdaq Real Time Price USD
Genetic Technologies Limited (GENE)
At close: October 16 at 4:00 PM EDT
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
7,664.7840
7,664.7840
8,686.1180
6,794.8160
120.5540
Cost of Revenue
3,760.3100
3,760.3100
4,335.2650
3,013.5340
170.4570
Gross Profit
3,904.4740
3,904.4740
4,350.8530
3,781.2820
-49.9030
Operating Expense
16,114.6860
16,114.6860
15,721.7380
12,887.7930
8,151.3240
Operating Income
-12,210.2120
-12,210.2120
-11,370.8850
-9,106.5110
-8,201.2270
Net Non Operating Interest Income Expense
-323.7380
-323.7380
-235.9430
-275.8420
31.4740
Other Income Expense
516.7310
516.7310
-302.4240
2,219.2300
1,092.1340
Pretax Income
-12,017.2190
-12,017.2190
-11,909.2520
-7,163.1230
-7,077.6190
Tax Provision
--
--
-158.3290
-32.1250
--
Net Income Common Stockholders
-12,017.2190
-12,017.2190
-11,750.9230
-7,130.9980
-7,077.6190
Diluted NI Available to Com Stockholders
-12,017.2190
-12,017.2190
-11,750.9230
-7,130.9980
-7,077.6190
Basic EPS
-0.03
--
-0.03
-0.02
-2.29
Diluted EPS
-0.03
--
-0.03
-0.02
-2.29
Basic Average Shares
4,612.2300
--
3,536.5380
3,216.4010
2,980.5200
Diluted Average Shares
4,612.2300
--
3,536.5380
3,216.4010
2,980.5200
Total Operating Income as Reported
-6,084.1070
--
--
--
--
Total Expenses
19,874.9960
19,874.9960
20,057.0030
15,901.3270
8,321.7810
Net Income from Continuing & Discontinued Operation
-12,017.2190
-12,017.2190
-11,750.9230
-7,130.9980
-7,077.6190
Normalized Income
-10,525.9340
-10,525.9340
-9,812.8245
-6,927.6371
-7,055.5740
Interest Income
119.5110
119.5110
220.1610
36.2560
62.3940
Interest Expense
51.6220
51.6220
29.5150
15.2150
16.3380
Net Interest Income
-323.7380
-323.7380
-235.9430
-275.8420
31.4740
EBIT
-11,965.5970
-11,965.5970
-11,879.7370
-7,147.9080
-7,061.2810
EBITDA
-11,430.7090
-11,430.7090
-11,203.1540
-6,569.2400
-6,675.0040
Reconciled Cost of Revenue
3,760.3100
3,760.3100
4,335.2650
3,013.5340
170.4570
Reconciled Depreciation
534.8880
534.8880
676.5830
578.6680
386.2770
Net Income from Continuing Operation Net Minority Interest
-12,017.2190
-12,017.2190
-11,750.9230
-7,130.9980
-7,077.6190
Total Unusual Items Excluding Goodwill
-1,491.2850
-1,491.2850
-1,964.2120
-204.2770
-22.0450
Total Unusual Items
-1,491.2850
-1,491.2850
-1,964.2120
-204.2770
-22.0450
Normalized EBITDA
-9,939.4240
-9,939.4240
-9,238.9420
-6,364.9630
-6,652.9590
Tax Rate for Calcs
--
--
0.0000
0.0000
--
Tax Effect of Unusual Items
--
--
-26.1135
-0.9161
--
6/30/2021 - 9/6/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BIAF bioAffinity Technologies, Inc.
1.3100
-1.50%
FUNI Hypha Labs, Inc.
0.0190
0.00%
SZLSF StageZero Life Sciences Ltd.
0.0244
0.00%
APDN Applied DNA Sciences, Inc.
0.1620
-6.79%
SZLS.TO StageZero Life Sciences Ltd.
0.0400
0.00%
ATLN Atlantic International Corp.
5.01
+0.20%
ACRS Aclaris Therapeutics, Inc.
2.0500
-5.96%
TTOO T2 Biosystems, Inc.
0.4970
-4.42%
STIM Neuronetics, Inc.
0.7100
-10.13%
NOTV Inotiv, Inc.
2.6800
-1.83%